Drugs (including oxygen) in severe COPD.

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Comprehensive guidelines for chronic obstructive pulmonary disease (COPD) management are available.
• Treatment goals identified from guidelines have been evaluated in clinical trials.
• Pharmacological interventions are crucial for managing COPD, especially in severe cases.

Purpose of the Study:

• To review current evidence on drug therapies for COPD management.
• To assess the appropriate prescription of new COPD treatments, including oxygen therapy.
• To evaluate the efficacy of various therapeutic agents and interventions.

Main Methods:

• Review of clinical trial data and guideline recommendations.
• Analysis of evidence for inhaled long-acting anticholinergic agents and steroids.
• Evaluation of data on prophylactic antibiotics, antioxidant agents, nutritional supplementation, statins, and oxygen therapy.

Main Results:

• Inhaled long-acting anticholinergic agents or combined inhaled steroids and long-acting beta-agonists are beneficial for patients with exacerbations.
• Evidence for prophylactic antibiotics and antioxidant agents is lacking.
• Nutritional supplementation does not improve exercise capacity.
• Long-term oxygen therapy in hypoxemic patients is robustly supported; ambulatory oxygen improves exercise capacity but may be overused.
• Short burst oxygen therapy offers no benefit.

Conclusions:

• Appropriate prescription of new COPD drug treatments, particularly oxygen, needs improvement.
• Long-term oxygen therapy is recommended for hypoxemic patients.
• Inhaled therapies are effective for managing COPD exacerbations.
• Further trials are needed to confirm the role of statins in COPD outcomes.